Investigational drug · Phase 2
HB0017
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Psoriasis (PsO).
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
6
Any phase or sponsor naming "HB0017"
First trial start
2024
Sep 30, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HB0017", any sponsor or status.
Conditions studied
As listed on its trial records.
- Psoriasis (PsO)
Approved drugs for the same conditions: Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "HB0017" as an intervention, largest first.
- Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque PsoriasisPivotal-lookingCompleted
Huabo Biopharm Co., Ltd.Industry
NCT06477237 · 408 participants · Start Mar 29, 2024 · Primary completion Nov 15, 2024
Drug: HB0017 Q4W; HB0017 Q8W and 1 more · For: Psoriasis
Sites: Jiangmen, China; Nanyang, China; Beijing, China · 44 sites in all
- A Phase 2 Study of HB0017 in Psoriasis PatientsPivotal-lookingCompleted
Huabo Biopharm Co., Ltd.Industry
NCT06592274 · 206 participants · Start Sep 30, 2024 · Primary completion Apr 30, 2025
Drug: HB0017; HB0017 and 1 more · For: Psoriasis (PsO)
Sites: Bengbu, China; Guangzhou, China; Changsha, China · 18 sites in all
- A Study to Evaluate the Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque PsoriasisPivotal-lookingCompleted
Huabo Biopharm Co., Ltd.Industry
NCT05531682 · 160 participants · Start Oct 25, 2022 · Primary completion May 23, 2023
Drug: HB0017 · For: Plaque Psoriasis
Sites: Bengbu, China; Hefei, China; Wuhu, China · 21 sites in all
Huabo Biopharm Co., Ltd.Industry
NCT07920861 · 90 participants (planned) · Start Jan 19, 2026 · Primary completion Dec 31, 2026
Drug: HB0017 Injection · For: Psoriasis; Ankylosing Spondylitis
Sites: Hangzhou, China
Huabo Biopharm Co., Ltd.Industry
NCT04505033 · 40 participants · Start Oct 2, 2020 · Primary completion Jan 2, 2021
Drug: HB0017; placebo · For: Healthy Subjects
Sites: Grafton, New Zealand
Huabo Biopharm Co., Ltd.Industry
NCT05442788 · 30 participants · Start Sep 2, 2021 · Primary completion May 31, 2022
Drug: HB0017 150mg or matching placebo; HB0017 300mg or matching placebo and 1 more · For: Plaque Psoriasis
Sites: Bengbu, China
Newest research
PubMed records naming it or its code names, newest first.
- Next-Generation Anti-IL-17 Agents for Psoriatic Disease: A Pipeline Review.
Kim D, Yang S, Gill M, et al. · Am J Clin Dermatol 2025
- Dual blockade of IL-17A and IL-36 pathways via a bispecific antibody exhibits enhanced anti-inflammatory potency.
Ma X, Zhang S, Ren X, et al. · Front Immunol 2024
- A study looking at a possible new drug, HB0017, for the treatment of psoriasis.
· Br J Dermatol 2023
- Safety, tolerability, pharmacokinetics and efficacy of HB0017, a humanized monoclonal antibody that targets interleukin-17A, in healthy participants and patients with moderate-to-severe plaque psoriasis.
Jiang C, Du Y, Liu X, et al. · Br J Dermatol 2023
- Structural and functional insights into a novel pre-clinical-stage antibody targeting IL-17A for treatment of autoimmune diseases.
Xu JG, Jia H, Chen S, et al. · Int J Biol Macromol 2022
Also in development for Psoriasis (PsO)
- Blinded EnvudeucitinibPhase 31 trial
Alumis Inc · Plaque Psoriasis, Psoriasis (PsO), Psoriasis
- Open-Label EnvudeucitinibPhase 31 trial
Alumis Inc · Plaque Psoriasis, Psoriasis (PsO), Psoriasis
- SFA002Phase 31 trial
SFA Therapeutics · Psoriasis (PsO)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.